ArticleFrontiers in public health2025
Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of China's national drug price negotiation on pharmaceutical firms' innovation activities.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In October 2017, China initiated adjustments to the registration procedures for imported drugs to promote accessibility to overseas drugs. In support of this decision, the National Medical Products Administration (NMPA) issued a technical guideline regarding accepting foreign clinical trial data in July 2018. Collectively referred to as the accepting foreign clinical data policy, these measures have accelerated the influx of overseas drugs into China. Methods: Using the panel data from 104 A-share pharmaceutical listed firms between 2013 and 2024, this study conducted a difference-in-differences model to explore the impact of this policy on the innovation investment of Chinese pharmaceutical firms and further analyzed the underlying moderating effect. Results: The results demonstrate a significantly positive effect of this accepting foreign clinical data policy on pharmaceutical firms' innovation investment, which is verified with the parallel trend and robustness tests. Further analysis indicates that corporate absorptive capacity positively moderates the relationship between the policy implementation and innovation investment. In addition, the heterogeneity analysis suggests that this policy has a more significant effect on firms that are non-state-owned, engage in new drug research and have strong market power. Discussion: This study serves as a significant supplement to the current literature regarding the accepting foreign clinical data policy and innovation investment, providing valuable insights for policymakers and R&D decision-makers in the pharmaceutical sector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.